NYSE:BMYPharmaceuticals
Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run?
Bristol-Myers Squibb stock has delivered a 31.9% return over the past year, yet its current valuation checks paint a mixed picture rather than a clear bargain or clear overpricing.
Over the last 12 months, Bristol-Myers Squibb is up 31.9%, which puts recent shareholder returns firmly in positive territory and raises the bar for what counts as good value from here.
On the supportive side, fresh oncology news such as the FDA accepting the New Drug Application for mezigdomide can underpin...